E Jonasch1, E Hasanov1, P G Corn1, T Moss1, K R Shaw1, S Stovall1, V Marcott1, B Gan1, S Bird1, X Wang1, K A Do1, P F Altamirano1, A J Zurita1, L A Doyle2, P N Lara3, N M Tannir1. 1. Division of Cancer Medicine, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson, Houston, TX, USA. 2. Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA. 3. UC Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Abstract
Background: Activation of the phosphoinisitide-3 kinase (PI3K) pathway through mutation and constitutive upregulation has been described in renal cell carcinoma (RCC), making it an attractive target for therapeutic intervention. We performed a randomized phase II study in vascular endothelial growth factor (VEGF) therapy refractory patients to determine whether MK-2206, an allosteric inhibitor of AKT, was more efficacious than the mammalian target of rapamycin inhibitor everolimus. Patients and methods: A total of 43 patients were randomized in a 2:1 distribution, with 29 patients assigned to the MK-2206 arm and 14 to the everolimus arm. Progression-free survival (PFS) was the primary endpoint. Results: The trial was closed at the first futility analysis with an observed PFS of 3.68 months in the MK-2206 arm and 5.98 months in the everolimus arm. Dichotomous response rate profiles were seen in the MK-2206 arm with one complete response and three partial responses in the MK-2206 arm versus none in the everolimus arm. On the other hand, progressive disease was best response in 44.8% of MK2206 versus 14.3% of everolimus-treated patients. MK-2206 induced significantly more rash and pruritis than everolimus, and dose reduction occurred in 37.9% of MK-2206 versus 21.4% of everolimus-treated patients. Genomic analysis revealed that 57.1% of the patients in the PD group had either deleterious TP53 mutations or ATM mutations or deletions. In contrast, none of the patients in the non-PD group had TP53 or ATM defects. No predictive marker for response was observed in this small dataset. Conclusions: Dichotomous outcomes are observed when VEGF therapy refractory patients are treated with MK-2206, and MK-2206 does not demonstrate superiority to everolimus. Additionally, mutations in DNA repair genes are associated with early disease progression, indicating that dysregulation of DNA repair is associated with a more aggressive tumor phenotype in RCC.
RCT Entities:
Background: Activation of the phosphoinisitide-3 kinase (PI3K) pathway through mutation and constitutive upregulation has been described in renal cell carcinoma (RCC), making it an attractive target for therapeutic intervention. We performed a randomized phase II study in vascular endothelial growth factor (VEGF) therapy refractory patients to determine whether MK-2206, an allosteric inhibitor of AKT, was more efficacious than the mammalian target of rapamycin inhibitor everolimus. Patients and methods: A total of 43 patients were randomized in a 2:1 distribution, with 29 patients assigned to the MK-2206 arm and 14 to the everolimus arm. Progression-free survival (PFS) was the primary endpoint. Results: The trial was closed at the first futility analysis with an observed PFS of 3.68 months in the MK-2206 arm and 5.98 months in the everolimus arm. Dichotomous response rate profiles were seen in the MK-2206 arm with one complete response and three partial responses in the MK-2206 arm versus none in the everolimus arm. On the other hand, progressive disease was best response in 44.8% of MK2206 versus 14.3% of everolimus-treated patients. MK-2206 induced significantly more rash and pruritis than everolimus, and dose reduction occurred in 37.9% of MK-2206 versus 21.4% of everolimus-treated patients. Genomic analysis revealed that 57.1% of the patients in the PD group had either deleterious TP53 mutations or ATM mutations or deletions. In contrast, none of the patients in the non-PD group had TP53 or ATM defects. No predictive marker for response was observed in this small dataset. Conclusions: Dichotomous outcomes are observed when VEGF therapy refractory patients are treated with MK-2206, and MK-2206 does not demonstrate superiority to everolimus. Additionally, mutations in DNA repair genes are associated with early disease progression, indicating that dysregulation of DNA repair is associated with a more aggressive tumor phenotype in RCC.
Authors: P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe Journal: Nature Date: 1999-05-20 Impact factor: 49.962
Authors: Mark Bi; Siming Zhao; Jonathan W Said; Maria J Merino; Adebowale J Adeniran; Zuoquan Xie; Cayce B Nawaf; Jaehyuk Choi; Arie S Belldegrun; Allan J Pantuck; Harriet M Kluger; Kaya Bilgüvar; Richard P Lifton; Brian Shuch Journal: Proc Natl Acad Sci U S A Date: 2016-02-10 Impact factor: 11.205
Authors: H Brauch; G Weirich; J Brieger; D Glavac; H Rödl; M Eichinger; M Feurer; E Weidt; C Puranakanitstha; C Neuhaus; S Pomer; W Brenner; P Schirmacher; S Störkel; M Rotter; A Masera; N Gugeler; H J Decker Journal: Cancer Res Date: 2000-04-01 Impact factor: 12.701
Authors: Axel S Merseburger; Joerg Hennenlotter; Ursula Kuehs; Perikles Simon; Stephan Kruck; Eva Koch; Arnulf Stenzl; Markus A Kuczyk Journal: Urol Int Date: 2008-06-27 Impact factor: 2.089
Authors: Eric Jonasch; Paul Corn; Lance C Pagliaro; Carla L Warneke; Marcella M Johnson; Pheroze Tamboli; Chaan Ng; Ana Aparicio; Robynne G Ashe; John J Wright; Nizar M Tannir Journal: Cancer Date: 2010-01-01 Impact factor: 6.860
Authors: Timothy A Yap; Li Yan; Amita Patnaik; Nina Tunariu; Andrea Biondo; Ivy Fearen; Kyriakos P Papadopoulos; David Olmos; Richard Baird; Liliana Delgado; Ernestina Tetteh; Robert A Beckman; Lisa Lupinacci; Ruth Riisnaes; Shaun Decordova; Simon P Heaton; Karen Swales; Nandita M deSouza; Martin O Leach; Michelle D Garrett; Daniel M Sullivan; Johann S de Bono; Anthony W Tolcher Journal: Clin Cancer Res Date: 2014-09-19 Impact factor: 12.531
Authors: Thomas Powles; Mark R Lackner; Stéphane Oudard; Bernard Escudier; Christy Ralph; Janet E Brown; Robert E Hawkins; Daniel Castellano; Brian I Rini; Michael D Staehler; Alain Ravaud; Wei Lin; Bridget O'Keeffe; Yulei Wang; Shan Lu; Jill M Spoerke; Ling-Yuh Huw; Michelle Byrtek; Rui Zhu; Joseph A Ware; Robert J Motzer Journal: J Clin Oncol Date: 2016-03-07 Impact factor: 44.544
Authors: Maria I Carlo; Ana M Molina; Yulia Lakhman; Sujata Patil; Kaitlin Woo; John DeLuca; Chung-Han Lee; James J Hsieh; Darren R Feldman; Robert J Motzer; Martin H Voss Journal: Oncologist Date: 2016-06-10
Authors: Luke Russell; Jessica Swanner; Alena Cristina Jaime-Ramirez; Yufeng Wang; Alex Sprague; Yeshavanth Banasavadi-Siddegowda; Ji Young Yoo; Gina M Sizemore; Raleigh Kladney; Jianying Zhang; Norman L Lehman; Michael C Ostrowski; Bangxing Hong; Michael Caligiuri; Jianhua Yu; Balveen Kaur Journal: Nat Commun Date: 2018-11-27 Impact factor: 14.919
Authors: Fabian Hofmann; Eu Chang Hwang; Thomas Bl Lam; Axel Bex; Yuhong Yuan; Lorenzo So Marconi; Börje Ljungberg Journal: Cochrane Database Syst Rev Date: 2020-10-14